
Opinion|Videos|February 10, 2025
Management of Tardive Dyskinesia and Comorbidities
Panelists discuss how managing tardive dyskinesia in patients with comorbid mental health conditions requires a delicate balance between treating TD symptoms while maintaining psychiatric stability, emphasizing the importance of coordinated care between psychiatrists and movement disorder specialists to optimize medication regimens, monitor for potential drug interactions, and address the complex interplay between physical symptoms and psychological well-being.
Advertisement
Episodes in this series

Video series above is prompted by the following:
- How does the burden of comorbid conditions, such as mental health disorders, influence the management and outcomes of patients with TD?
- How does the long-term management of TD align with treatment strategies for other movement disorders, and what challenges or opportunities arise when managing coexisting conditions
Advertisement
Related to this article

Adults with AChR antibody–positive generalized myasthenia gravis now have a C5 inhibitor they can inject themselves at home once a week.

Peer Reviewed
Semaglutide-Associated Sensory Skin Disturbance in Patients Without Diabetes Treated for Weight Loss
This case series describes 2 instances of cutaneous sensory disturbance during semaglutide therapy in patients without diabetes and discusses possible mechanisms as hypotheses requiring further investigation.

Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.

Dexmedetomidine is approved, becoming the first at-home treatment for schizophrenia-associated agitation.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

The anti-CD20 antibody is the first drug approved specifically for the disease, based on phase 3 MAJESTY data showing higher remission vs tacrolimus.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
Blood Glucose Testing: When Nonadherence Isn't the Real Issue
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
Dexmedetomidine Receives FDA Approval for Acute Treatment for Agitation Associated With Schizophrenia
5



